Trial · NCT06687876
Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy
NCT06687876, Phase 2, Recruiting, Amsterdam UMC, location VUmc
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy. Trials, record NCT06687876. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06687876
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy
- NCT number
- NCT06687876
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 14 participants, estimated
- Lead sponsor
- Amsterdam UMC, location VUmc
- Conditions
- Oesophageal Adenocarcinoma, Tumor Microenvironment
- Interventions
- Metformin
- First posted
- 2024-11-14
- Last updated
- 2025-07-10
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | activation of the tumour immune microenvironment after two week metformin treatment. | at enrollment and at end of metformin treatment at 2 weeks. | Activation of the tumor immune microenvironment measured by M2 to M1 polarization, CD8 intratumoral T cell infiltration and an increase of CD3 to CD163 ratio when comparing tumor biopsies from before and after treatment. |
| Secondary | Tolerability and toxicity of metformin | From starting treatment to end of treatment at 7 weeks. | Adverse events based on Common Toxicity Criteria for Adverse Events |
| Secondary | Metabolic change of cancer cells with SCENITH analysis. | at enrollment and at end of metformin treatment at 2 weeks | To determine whether SCENITH can be used to assay the change in metabolic state. |
| Secondary | Pathological response | After surgery, approximately 16 weeks after enrollment. | According to the Mandard criteria. |
| Secondary | Progression-free survival (PFS). | 60 months | Assess the PFS of patients within the study |
| Secondary | Overall survival (OS) | 60 months | Determine overall survival of patients within the study |
| Other | Can metformin induce a metabolic switch in macrophages, T cells and cancer cells. | 20 months | Using single cell RNA sequencing or SCENITH analysis. |
| Other | Change in subgroups in peripheral blood mononuclear cells (PMBCs) after metformin treatment. | 20 months | Are the changes to the tumour immune microenvironment also detected in subgroups of peripheral blood mononuclear cells (PBMCs) taken at the same time points. |
| Other | Establish immune cell co-cultures with primary tumour cells and investigate the cell interactions and anti-tumour responses in presence of metformin. | 20 months | Establish autologous immune cell co-cultures with primary tumor cells to investigate immune cell-tumor cell interactions and anti-tumour responses in the presence of metformin. |
| Other | Cytokine release profile measured in serum before and after metformin treatment. | 20 months | Determine changes in cytokine expression in serum before and after metformin treatment. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06687876
GET https://conductscience.org/api/trials/v1/NCT06687876/registered